BFM
ADMS

Boothbay Fund Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Boothbay Fund Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-18,375
Closed -$47K – 1323
2020
Q2 		$47K Buy
18,375
+875
+5% +$2.57K ﹤0.01% 917
2020
Q1 		$51K Buy
+17,500
New +$78.4K ﹤0.01% 784
2019
Q4 		– Sell
-31,000
Closed -$159K – 1063
2019
Q3 		$159K Buy
+31,000
New +$191K 0.01% 669

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Boothbay Fund Management's ADMS Position: Q3 2020 in Review

Boothbay Fund Management sold out of Adamas Pharmaceuticals (ADMS) in Q3 2020, closing a stake of 18,375 shares — an estimated $47K sold.

Boothbay Fund Management first reported a position in ADMS in Q3 2019 and held it in 3 quarters. The position peaked at $159K in Q3 2019. 63 funds tracked by Wall St. Rank hold ADMS as of Q3 2020.

  • Boothbay Fund Management reported no remaining Adamas Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Boothbay Fund Management sold 18,375 Adamas Pharmaceuticals shares in Q3 2020, an estimated $47K.
  • Boothbay Fund Management first reported a position in Adamas Pharmaceuticals in Q3 2019 and held it in 3 quarters.
  • Boothbay Fund Management's Adamas Pharmaceuticals position peaked at $159K in Q3 2019.
  • 63 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2020.

Based on Boothbay Fund Management's 13F filing for Q3 2020, filed 16 Nov 2020.